Recipharm commits SEK5m to bioanalysis lab citing lack of Nordic capacity

By Gareth Macdonald contact

- Last updated on GMT

Recipharm commits SEK5m to bioanalysis lab citing lack of Nordic capacity

Related tags: Sweden

Recipharm has said it will spend SEK5m ($567,000) on a bioanalysis laboratory in Sweden citing the lack of capacity in the Nordic region as a driver for the investment.

The contract manufacturing firm said it will build the new lab at a site in Uppsala, Sweden, explaining that the facility will have capacity to process 10,000 plasma samples a week.

Fredrik Lehmann, General Manager at Recipharm Development in Uppsala told us the laboratory will offer a range of bioanalysis services, with a focus on the assessment of clinical and toxicology samples.

He added that the site will conduct bioanalysis work for a variety of drug types “mostly small molecule, but not exclusively, some large molecules will also be handled​.”

Nordic capacity

Sweden is a base of operations for some of the largest drug manufacturers in the world. For example, Pfizer and AstraZeneca both have production operations in the country.

But there is a lack of good laboratory practice (GLP) standard bioanalysis labs in Sweden and across the Nordic region as a whole according to Lehmann, who cited the shortage alongside customer demand as a driver for the investment.

Some major pharma might, or might not, have capacity in-house, but looking at all the GLP certificates that are issued in Sweden, there are not that many​” he said, adding that “and the majority of those GLP labs do not perform bioanalysis.”

At present Recipharm contracts bioanalysis work to a third party laboratory. However, according to Lehmann “we will not continue working with that vendor now that we have the capacity in-house​.”

The firm plans to recruit several chemists in the coming months and aims to more than double its team of 35 in the next couple of years.

Related topics: Bio Developments, Bio-Outsourcing

Related news

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more